Search results
Showing 91 to 105 of 148 results for allergy
Cellvizio confocal endomicroscopy system for characterising pancreatic cysts (MIB69)
Advice on the use of Cellvizio confocal endomicroscopy system (CLS) for characterising pancreatic cysts to aid local decision-making
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
LiMAx system for assessing the functional capacity of the liver (MIB168)
NICE has developed a medtech innovation briefing (MIB) on LiMAx system for assessing the functional capacity of the liver .
NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
Discontinued Reference number: GID-TA10597
This guideline covers managing spasticity and co-existing motor disorders and their early musculoskeletal complications in children and young people (from birth up to their 19th birthday) with non-progressive brain disorders. It aims to reduce variation in practice and help healthcare professionals to select and use appropriate treatments.
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Discontinued Reference number: GID-TA10764
NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)
This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.
Pharmalgen for the treatment of bee and wasp venom allergy (TA246)
This guidance has been withdrawn because Pharmalgen products no longer have a marketing authorisation in the UK.
Otovent nasal balloon for otitis media with effusion (MIB59)
NICE has developed a medtech innovation briefing (MIB) on the Otovent nasal balloon for otitis media with effusion
NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]
In development Reference number: GID-TA11070 Expected publication date: TBC
In development Reference number: GID-TA11352 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on Biopatch for venous or arterial catheter sites .